Jacob Beneby Help Him Smile Again: 10 Pound Tumor in His Face is Painful & Debilitating: Donate Now

December 21, 2020

Jacob Beneby is a 46-year-old adult living with this tumor for the past 3 decades. After multiple failed surgeries, the tumor continues to grow. The tumor has him in critical pain and unable to function normally. It is estimated that this tumor weighs 10 pounds.

Jacob Beneby and his wife were flown to Florida to meet with Dr. Roland Hernandez. After reviewing his case, it was found that the tumor was growing from the inside and outside of his jaw and a series of surgeries would be needed to bring him back to health. Jaw replacement would be the only way to fully get rid of this aggressive tumor.

Jacob’s family has created a GoFundMe account in order to obtain help with the cost of medications and their stay while Jacob recovers from surgery. Their 4 children are back home in the Bahamas and can’t wait to see their parents again.

 “Every day the tumor is growing. Time is of the essence” – Princess Beneby

The following procedures needed to help Jacob include:

●  Dr. Roland Hernandez, Chief of the Department of Oral and Maxillofacial Surgery at Broward Health Medical Center and Memorial Regional Hospital, along with a team of medical professionals from Memorial Regional Hospital will remove the jaw and immediately reconstruct it with a custom titanium reconstruction plate (donated by Stryker Corporation). This plate will resuspend the tongue muscle and his airway while simultaneously giving him a normal appearance.

●  Once healed from his first surgery, definitive reconstructive surgery will occur in which bones from other parts of Jacob’s body will be harvested to reconstruct his face.

●  The last phase will occur two years after his reconstructive surgery. Dental surgery will take place by placing dental implants where a denture can be fixated to it which will finally help Jacob Beneby achieve his dream of chewing food and having a smile again.

The family thanks Dr. Roland Hernandez, the team at Memorial Regional Hospital, and Stryker Corporation for this act of kindness and hopes that Jacob can finally smile again. To donate to their cause, please visit their GoFundMe page.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version